Background: Human immunodeficiency virus (HIV)-infected patients are surviving longer since the advent of antiretroviral therapy. Therefore, more patients are developing non-AIDS-defining cancers which increasingly determine mortality. Case Reports: Here we present 2 cases of locally advanced non-small cell lung cancer treated initially with concomitant chemoradiotherapy and antiretroviral therapy. Both patients were male, ages 69 and 66, with known HIV infection and immunologically stable on antiretroviral therapy. Presenting symptoms included superior sulcus tumor with left arm immobility and sensory disturbance in case 1 and right lower bronchus constriction in case 2. Symptoms were controlled by chemoradiotherapy. Conclusion: These cases illustrate that intensive anticancer therapy administered to the HIV-infected population can be tolerated even though these patients seem to be too fragile for both chemotherapy and radiotherapy, especially since the potential benefit remains uncertain. Recent improvements in chemoradiotherapy and supportive care have enhanced tolerance for such therapy.

Keywords:
Non-small cell lung cancer, NSCLC, Human immunodeficiency virus, HIV, Highly active antiretroviral therapy, HAART, Locoregionally advanced NSCLC, Chemoradiotherapy, Non-AIDS-defining cancers
1.
Sepkowitz KA: AIDS - the first 20 years. N Engl J Med 2001;344:1764-1772.
2.
Lavole A, Wislez M, Antoine M, Mayaud C, Milleron B, Cadranel J: Lung cancer, a new challenge in the HIV-infected population. Lung Cancer 2006;51:1-11.
3.
D'Jaen GA, Pantanowitz L, Bower M, Buskin S, Neil N, Greco EM, Cooley TP, Henry D, Stem J, Dezube BJ, Stebbing J, Aboulafia DM: Human immunodeficiency virus-associated primary lung cancer in the era of highly active antiretroviral therapy: a multi-institutional collaboration. Clin Lung Cancer 2010;11:396-404.
4.
Engels EA, Brock MV, Chen J, Hooker CM, Gillison M, Moore RD: Elevated incidence of lung cancer among HIV-infected individuals. J Clin Oncol 2006;24:1383-1388.
5.
Alshafie MT, Donaldson B, Oluwole SF: Human immunodeficiency virus and lung cancer. Br J Surg 1997;84:1068-1071.
6.
Bower M, Powles T, Nelson M, Shah P, Cox S, Mandelia S, Gazzard B: HIV-related lung cancer in the era of highly active antiretroviral therapy. AIDS 2003;17:371-375.
7.
Lavole A, Cadranel J: (Lung cancer in patients with HIV infection: an emerging problem). Rev Pneumol Clin 2004;60:4S39-34S43.
8.
Karp J, Profeta G, Marantz PR, Karpel JP: Lung cancer in patients with immunodeficiency syndrome. Chest 1993;103:410-413.
9.
Flores MR, Sridhar KS, Thurer RJ, Saldana M, Raub WA Jr, Klimas NG: Lung cancer in patients with human immunodeficiency virus infection. Am J Clin Oncol 1995;18:59-66.
10.
Bazoes A, Bower M, Powles T: Smoke and mirrors: HIV-related lung cancer. Curr Opin Oncol 2008;20:529-533.
11.
Giordano TP, Kramer JR: Does HIV infection independently increase the incidence of lung cancer? Clin Infect Dis 2005;40:490-491.
12.
Pakkala S, Chen Z, Rimland D, Owonikoko TK, Gunthel C, Brandes JR, Saba NR, Shin DM, Curran WJ Jr, Khuri FR, Ramalingam SS: Human immunodeficiency virus-associated lung cancer in the era of highly active antiretroviral therapy. Cancer 2011;118:164-172.
13.
Cadranel J, Garfield D, Lavole A, Wislez M, Milleron B, Mayaud C: Lung cancer in HIV infected patients: facts, questions and challenges. Thorax 2006;61:1000-1008.
14.
Hakimian R, Fang H, Thomas L, Edelman MJ: Lung cancer in HIV-infected patients in the era of highly active antiretroviral therapy. J Thorac Oncol 2007;2:268-272.
15.
Rengan R, Mitra N, Liao K, Armstrong K, Vachani A: Effect of HIV on survival in patients with non-small-cell lung cancer in the era of highly active antiretroviral therapy: a population-based study. Lancet Oncol 2012;13:1203-1209.
16.
Kaminuma T, Karasawa K, Hanyu N, Chang TC, Kuga G, Okano N, Kubo N, Okuma Y, Nagata Y, Maeda Y, Ajisawa A: Acute adverse effects of radiation therapy on HIV-positive patients in Japan: study of 31 cases at Tokyo Metropolitan Koma-gome Hospital. J Radiat Res (Tokyo) 2010;51:749-753.
17.
Chak LY, Gill PS, Levine AM, Meyer PR, Anselmo JA, Petrovich Z: Radiation therapy for acquired immunodeficiency syndrome-related Kaposi's sarcoma. J Clin Oncol 1988;6:863-867.
18.
Cooper JS, Fried PR, Laubenstein LJ: Initial observations of the effect of radiotherapy on epidemic Kaposi's sarcoma. JAMA 1984;252:934-935.
19.
Buhl R, Jaffe HA, Holroyd KJ, Wells FB, Mastrangeli A, Saltini C, Cantin AM, Crystal RG: Systemic glutathione deficiency in symptom-free HIV-seropositive individuals. Lancet 1989;2:1294-1298.
20.
Vallis KA: Glutathione deficiency and radiosensitivity in aids patients. Lancet 1991;337:918-919.
21.
Chapman CH, Shen J, Filion EJ, Tran PT, Hara W, Asuncion A, Marko D, Wakelee H, Berry GJ, Dimmick KW, Loo BW Jr, Green J: Marked tumor response and fatal hemoptysis during radiation for lung cancer in a human immunodeficiency virus-positive patient taking nelfinavir. J Thorac Oncol 2009;4:1587-1589.
22.
Brunner TB, Geiger M, Grabenbauer GG, Lang-Welzenbach M, Mantoni TS, Cavallaro A, Sauer R, Hohenberger W, McKenna WG: Phase I trial of the human immunodeficiency virus protease inhibitor nelfinavir and chemoradiation for locally advanced pancreatic cancer. J Clin Oncol 2008;26:2699-2706.
23.
Sanchez X, Cousins-Hodges B, Aguilar T, Gosselink P, Lu Z, Navarro J: Activation of HIV-1 coreceptor (CXCR4) mediates myelosuppression. J Biol Chem 1997;272:27529-27531.
24.
Chow WA, Jiang C, Guan M: Anti-HIV drugs for cancer therapeutics: back to the future? Lancet Oncol 2009;10:61-71.
© 2013 S. Karger GmbH, Freiburg
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.